ArticleDiscover oncology2025
UBE2C-mediated ubiquitination of ACSL4 inhibits ferroptosis and promotes gastric cancer progression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exosomal circPDSS1 Derived From Gastric Cancer Cells Promotes Natural Killer Cell Ferroptosis by Regulating the miR-142-3p/ACSL4 Molecular Axis.Applied biochemistry and biotechnology · 2026Article
- The UBE2/E2 ubiquitin-conjugating enzyme family at the interface of tumor biology and antitumor immunity: mechanisms, biomarkers, and therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Gastric cancer (GC) is a major malignancy with a poor prognosis and high recurrence rate. The role of UBE2C, an E3 ubiquitin ligase, in gastric cancer progression was investigated. Data from TCGA and GEO datasets revealed significant upregulation of UBE2C in gastric cancer tissues, with a negative correlation between UBE2C and ACSL4, a key regulator of ferroptosis. The expression of UBE2C was manipulated in gastric cancer cell lines, and silencing of UBE2C significantly reduced cell proliferation, migration, and invasion. Additionally, an increase in reactive oxygen species (ROS) and iron ion accumulation suggested that UBE2C inhibition could promote ferroptosis. Further experiments showed that UBE2C ubiquitinates ACSL4, leading to its degradation, which suppressed ferroptosis in gastric cancer cells. Rescue experiments confirmed that silencing ACSL4 reversed the effects of UBE2C on cell proliferation and migration. In vivo experiments with GSH treatment alleviated the tumor-promoting effects of UBE2C overexpression, further supporting the regulatory role of UBE2C in ferroptosis. These findings suggest that UBE2C-mediated inhibition of ferroptosis through the ubiquitination of ACSL4 contributes to gastric cancer progression, and targeting this pathway may offer a new therapeutic strategy for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.